CMS TAVR coverage expansion proposal and positive analyst notes drive EW gain
- CMS posted proposed Medicare coverage expansion for TAVR (CAG-00430R2) around June 15-16, boosting procedure volume expectations.
- Analysts (RBC, Leerink, Evercore ISI) called proposal 'incrementally positive' and 'uber bullish' for Edwards' structural heart sales.
- TAVR remains core revenue driver; proposal seen aiding hospital adoption and patient access per MedTech Dive and TipRanks reports.
- Follows Q1 2026 beat with raised full-year sales (9-11%) and EPS guidance, sustaining positive momentum into late June.
- New York Valves conference (June 24-26) likely amplified sector focus on Edwards' innovations.
- Shares rose ~3.6-4% intraday June 24 from $86.96 prior close, trading near $90 with elevated volume.
- Builds on mid-June 3.4-3.6% jump; no offsetting negative news identified.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.